Header
“Say we divide the cardio-renal continuum in 4 parameters; 3-point MACE, CV death, HF/hHF, renal impairment. Empagliflozin scores 4 on 4, through all the trials done, it shows significant benefit in all 4 parameters. Linagliptin scores 4 on 4 as it shows neutrality in all 4 parameters. Together EMPA + LINA is 8 on 8 for all these parameters”
“Fixed drug combination of Empagliflozin and Linagliptin is proving to be very successful. There is great logic in combining these two drugs. Both of them are not associated with weight gain and both of them are not associated with hypoglycaemia. When you combine Linagliptin with Empagliflozin, even the genital tract infections seem to come down.”
“A combination of DDP4 inhibitor like Linagliptin and a SGLT2 inhibitor like Empagliflozin is an ideal combination because both of them do not produce hypoglycaemia. One of the most important factor for aggressive therapy in early diabetes is hypoglycaemia, especially when you’re using sulfonylureas or insulin. Therefore, a combination of DDP4 inhibitor and a SGLT2 inhibitor is an ideal combination to start early in the treatment of Type 2 Diabetes.”
“Some of my patients those who are not on antidiabetic drugs, turn out to be having diabetes and they have cardiovascular disease. Instead of putting them on Metformin, I am following the ESC guidelines and straight away putting them onto fixed dose combination and it is working very well!”                                                                                                                                                                                                                                                                    
“If you have to add two drugs to Metformin, or if you want to be aggressive in your treatment, using a fixed dose combination of a gliptin and a SGLT2i makes a lot of sense. Because you are not risking the patient with hypoglycaemia in any way, and you are providing aggressive glucose control. At the same time, you are helping the patient lose weight and most importantly you are actually reducing the risk of long-term complications of heart and kidney.”                                                                                                                                                                                      
“A combination of DDP4 inhibitor like Linagliptin and a SGLT2 inhibitor like Empagliflozin is an ideal combination because both of them do not produce hypoglycaemia” ….“ Therefore, a combination of a DDP4 inhibitor and a SGLT2 inhibitor is an ideal combination to start early in the treatment of Type 2 Diabetes. For the first reason, it targets pathophysiology. For the second reason, it does not produce hypoglycaemia. Third reason; it reduces HbA1c upto 1.8%, and fourth reason; in the long run, it reduces the risk of cardiovascular and renal complications.”
“Together this combination is synergistic in not just reducing the occurrence of urogenital infections but also in bringing down HbA1c to a robust level. I hope that more and more will use the combination of Empagliflozin and Linagliptin which will bring down the HbA1c with weight benefits, weight loss without hypoglycaemia so that glucose control can be steady and in turn this will prevent them from developing diabetes related complications.”